Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cerep sales flat in the first half

This article was originally published in Scrip

Executive Summary

Sales revenues at the French pharmaceutical services firm Cerep were flat during the first half of the year, totalling €14.2 million compared with €14.98 million in the first half of 2007, although at constant exchange rates revenues would have increased by 3.5% to €15.5 million. In vitro ADME activities at its US subsidiary showed a 44.8% increase, while revenues from pharmacological profiling dropped by 5.6% at constant exchange rates. The financial results were affected by budgetary restrictions at some pharmaceutical companies, and by delays in the start of some multiyear collaboration contracts, Cerep says. Consolidated EBITDA from continuing activities was €0.49 million compared with €1.48 million in the previous six-month period. In April, Cerep entered a supply and co-marketing agreement with Perkin Elmer on target screening and profiling services, and in May it opened an additional 10,200 ft2 of laboratories and offices in Redmond, Washington.

You may also be interested in...



Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840

Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.

Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study

Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC003168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel